Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 5Stomatitis 3Head and Neck Neoplasms 3Fatigue 3Colorectal Neoplasms 3Pain 2Multiple Myeloma 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Ulcer 1Trauma, Nervous System 1Spondylitis, Ankylosing 1Skin Neoplasms 1Schwannomatosis 1Rectal Neoplasms 1Psoriasis 1Pleural Effusion, Malignant 1Pancreatic Cyst 1Ovarian Neoplasms 1Non-functioning Pituitary Adenoma 1Neurofibromatosis 1 1Neurilemmoma 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Mesothelioma 1Malignant Neoplasm of Colorectum 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Octreotide 3Capecitabine 3Temozolomide 2Everolimus 2Bortezomib 2vatalanib 1romidepsin 1regorafenib 1pazopanib 1pasireotide 1motesanib diphosphate 1fluorodopa F 18 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Solutions 1Saline Solution 1Panobinostat 1Melphalan 1Leucovorin 1Irinotecan 1Injections 1Gefitinib 1Fluorouracil 1Cisplatin 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Insulinoma × Saline Solution × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡